$10.25
+0.86 (+9.16%)
Open$9.49
Previous Close$9.39
Day High$10.33
Day Low$9.46
52W High$20.56
52W Low$4.64
Volume—
Avg Volume181.9K
Market Cap163.88M
P/E Ratio—
EPS$-5.98
SectorBiotechnology
Analyst Ratings
Strong Buy
16 analysts
Price Target
+18.5% upside
Current
$10.25
$10.25
Target
$12.15
$12.15
$8.71
$12.15 avg
$17.60
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 72.40M | 73.75M | 70.02M |
| Net Income | -2,537,554 | -2,715,843 | -3,439,667 |
| Profit Margin | -3.5% | -3.7% | -4.9% |
| EBITDA | -3,891,696 | -4,515,140 | -4,413,459 |
| Free Cash Flow | -4,239,895 | -2,837,667 | -3,192,005 |
| Rev Growth | +4.2% | -7.8% | -7.0% |
| Debt/Equity | 0.37 | 0.31 | 0.36 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |